As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Altimmune, Inc. The largest reported stake is Deep Track Capital, LP's, at 9.99%. 9 filings are on record since July 16, 2025 (Schedule 13G, April 30, 2026).
Sell to companies like Altimmune, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 666,022 · Sole dispositive: 0 · Shared dispositive: 666,022 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 7,012,433 · Sole dispositive: 0 · Shared dispositive: 7,145,550 · SCHEDULE 13G, 2026-05-12
- · Reporting person: Viking Global Investors LP · Sole voting: 0 · Shared voting: 13,400,000 · Sole dispositive: 0 · Shared dispositive: 13,400,000 · SCHEDULE 13G, 2026-05-01
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 13,000,000 · Sole dispositive: 0 · Shared dispositive: 13,000,000 · SCHEDULE 13G, 2026-05-01
- · Holder: Chen Yu · Percent: 9.8% · SCHEDULE 13G
Altimmune, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Deep Track Capital, LP | 9.99% | 19,417,221 | SCHEDULE 13G, 2026-04-30 | 2026-04-23 |
| 9.8% | 20,000,000 | SCHEDULE 13G, 2026-05-01 | 2026-04-24 | |
| BlackRock, Inc. | 7.6% | 6,133,427 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Viking Global Investors LP | 6.7% | 13,400,000 | SCHEDULE 13G, 2026-05-01 | 2026-04-24 |
| RA Capital Management, L.P. | 6.5% | 13,000,000 | SCHEDULE 13G, 2026-05-01 | 2026-04-24 |
| State Street Corporation | 5.5% | 7,145,550 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| Tang Capital Management, LLC | 0.3% | 666,022 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Altimmune, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Altimmune, Inc. and the records around it.
Altimmune, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Altimmune, Inc.
Get an email when Altimmune, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Altimmune, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Altimmune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Altimmune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Viking Global Investors LP | 0 | 13,400,000 | 0 | 13,400,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Parent GP LLC | 0 | 13,400,000 | 0 | 13,400,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities GP LLC | 0 | 9,380,000 | 0 | 9,380,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Portfolio GP LLC | 0 | 9,380,000 | 0 | 9,380,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 0 | 9,380,000 | 0 | 9,380,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Vintage IV GP LLC | 0 | 4,020,000 | 0 | 4,020,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Vintage IV Portfolio GP LLC | 0 | 4,020,000 | 0 | 4,020,000 | SCHEDULE 13G, 2026-05-01 |
| Viking Global Opportunities Vintage IV (Aggregator) LP | 0 | 4,020,000 | 0 | 4,020,000 | SCHEDULE 13G, 2026-05-01 |
| Halvorsen Ole Andreas | 0 | 13,400,000 | 0 | 13,400,000 | SCHEDULE 13G, 2026-05-01 |
| Shabet Rose Sharon | 0 | 13,400,000 | 0 | 13,400,000 | SCHEDULE 13G, 2026-05-01 |
| RA Capital Management, L.P. | 0 | 13,000,000 | 0 | 13,000,000 | SCHEDULE 13G, 2026-05-01 |
| Peter Kolchinsky | 0 | 13,000,000 | 0 | 13,000,000 | SCHEDULE 13G, 2026-05-01 |
| Rajeev Shah | 0 | 13,000,000 | 0 | 13,000,000 | SCHEDULE 13G, 2026-05-01 |
| RA Capital Healthcare Fund, L.P. | 0 | 13,000,000 | 0 | 13,000,000 | SCHEDULE 13G, 2026-05-01 |
| State Street Corporation | 0 | 7,012,433 | 0 | 7,145,550 | SCHEDULE 13G, 2026-05-12 |
| Tang Capital Management, LLC | 0 | 666,022 | 0 | 666,022 | SCHEDULE 13G/A, 2026-05-15 |
| Kevin Tang | 0 | 666,022 | 0 | 666,022 | SCHEDULE 13G/A, 2026-05-15 |
| Tang Capital Partners, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Tang Capital Partners International, LP | 0 | 666,022 | 0 | 666,022 | SCHEDULE 13G/A, 2026-05-15 |
| Tang Capital Partners Iii, Inc | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Tang Capital Partners Iv, Inc | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Altimmune, Inc. by CUSIP 02155H200 and gives its principal executive office as 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878 (SCHEDULE 13G/A, 2026-05-15).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-05-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 7.6% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 9.09% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Deep Track Capital, LP | 9.99% | SCHEDULE 13G |
| 2026-05-01 | Viking Global Investors LP | 6.7% | SCHEDULE 13G |
| 2026-05-01 | Chen Yu | 9.8% | SCHEDULE 13G |
| 2026-05-01 | RA Capital Management, L.P. | 6.5% | SCHEDULE 13G |
| 2026-05-12 | State Street Corporation | 5.5% | SCHEDULE 13G |
| 2026-05-15 | Tang Capital Management, LLC | 0.3% | SCHEDULE 13G/A |
Questions about who owns Altimmune, Inc.
Who owns Altimmune, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Altimmune, Inc.: Deep Track Capital, LP (9.99%, Schedule 13G, filed 2026-04-30), Chen Yu (9.8%, Schedule 13G, filed 2026-05-01), BlackRock, Inc. (7.6%, Schedule 13G/A, filed 2025-07-16), Viking Global Investors LP (6.7%, Schedule 13G, filed 2026-05-01) and RA Capital Management, L.P. (6.5%, Schedule 13G, filed 2026-05-01); 1 more is listed above.
Who are the largest shareholders of Altimmune, Inc.?
By the share each holder's latest filing reports, the largest holders of Altimmune, Inc. on this page are Deep Track Capital, LP (9.99%), Chen Yu (9.8%) and BlackRock, Inc. (7.6%).
When did Deep Track Capital, LP buy into Altimmune, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Deep Track Capital, LP on this page is the Schedule 13G, filed 2026-04-30, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Altimmune, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 29, 2026 | Leadership change: Richard Menziuso appointed, Vice President, Global Controller and Principal Accounting | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Altimmune, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.